Trouble reading this email? View it in your browser
European Federation of Pharmaceutical Industries and Associations EFPIA Newsletter 19 March 2026
      The price of hesitation — Why Europe’s ​​​e​​​​​​​conomic ​​​f​​​​​​​uture ​​​d​​​​​​​epends on ​​​h​​​​​​​ealth ​​​i​​​​​​​nnovation​​.
 
 
By Teresa Graham, CEO​,​ ​​Roche Pharmaceuticals​; and​ ​​Vice President, ​​​​​​EFPIA...
 

European governments navigate an ever more competitive global landscape, stagnating productivity and competing demands on budgets. We have successfully faced and solved many challenges in the past, but this situation is different: the choices we make today will shape our health​ ​care systems and patient care, and these choices will dictate Europe’s economic performance and global relevance for decades to come.

For those of us in the life sciences, these aren’t just macroeconomic trends — they are the pulse of a system that determines how quickly a breakthrough reaches a patient. It is a high-stakes environment where policies on health​ ​care and innovation carry urgent human and economic consequences. 

Read more →
 
 
      Turning EU excellence in science into commercial success could add more than €120billion to EU economy in 10 years
New research for EFPIA by Charles River Associates provides the first comprehensive overview of the EU’s attractiveness as a destination for pharmaceutical investment, benchmarked against its global competitors: US, China, UK and Switzerland.

While Europe retains important strengths, other regions have rolled out ambitious strategies to attract investment, innovation and talent.

How can Europe keep pace?

Read more here.

 

      Improving Europe’s water quality: watch Euractiv’s event recording

On 17 March, we were pleased to take part in the Euractiv hybrid conference Improving Europe’s Water Quality: How can the revised UWWTD be implemented fairly and effectively?

As Nathalie Moll, EFPIA Director General, highlighted, “we all share the same objective of having clean water in Europe,” while stressing the need for “a fair share of the cost among all the polluters present in the water,” based on transparent, science-based data to ensure the right balance between environmental goals, patient access to medicines, and Europe’s competitiveness.

Watch the recording here.

 
 
      Events
 
 
19 MAR 2026
  J&J | The essentials of partnering with a pharma company Utrecht & Virtual

Discover what it takes to build successful collaborations with pharmaceutical companies and accelerate your innovation...

Learn more →
 
 
 
 
24 MAR 2026
  POLITICO Competitive Europe Summit 2026 Brussels, Belgium

Caught between geopolitical turmoil, mounting pressure to deliver growth and war raging at its doorstep, the EU stands...

Learn more →
 
 
 
 
24 MAR 2026
  DIA Europe 2026 Rotterdam, Netherlands

Join the DIA Europe 2026 in March to explore how Europe can bring and keep innovation into the system to deliver better...

Learn more →
 
 
 
 
21 APR 2026
  Europe’s Choice: Investing in sustainable health systems Brussels, Belgium

At a time when health budgets are strained, public finances are under pressure, the health workforce crisis is deepening,...

Learn more →
 
 
 
 
      What we are reading
New PRIME tools to accelerate development of medicines in the EU 18 March 2026  (European Medicines Agency)

EMA launched three major new features of PRIME, the Agency’s scheme to enhance support for the development of medicines...

Read more →
Respiratory infections and long-term illness: a two-way street 18 March 2026  (Vaccines Today)

Until recently, long-term conditions (such as diabetes, obesity, cardiovascular disease and cancer) were seen as...

Read more →
Fostering greater collaboration in rare disease research 16 March 2026  (Rare Revolution Magazine)

Collaboration lies at the heart of rare disease research because its unique challenges can only be overcome by working...

Read more →
 
    About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

 
Tel: +32 (0)2 626 25 55
Communications@efpia.eu
X in
 
EFPIA 2026 All rights reserved  ·  Disclaimer  ·  Unsubscribe